Critical Outcome Technologies Inc.
TSX VENTURE : COT

Critical Outcome Technologies Inc.

January 21, 2008 11:36 ET

Critical Outcome Technologies Inc. Announces Officer's Donation of Shares to London Health Sciences Foundation

LONDON, ONTARIO--(Marketwire - Jan. 21, 2008) - Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced today that Dr. Wayne Danter, President & CSO and Mr. Gene Kelly, CFO, have each donated 25,000 common shares of Critical Outcome Technologies Inc. (COTI) to the London Health Sciences Foundation (LHSF). Upon sale, these shares are expected to realize net proceeds of approximately $50,000 to $60,000 to LHSF.

LHSF is a non-profit, charitable organization established to strengthen London Health Sciences Centre's (LHSC) ability to provide health care of the highest quality to patients in Southwestern Ontario and beyond. LHSC is one of Canada's largest teaching hospitals consisting of three distinct sites and employing over 9,000 people. The staff and physicians at LHSC care for approximately one million inpatient, outpatient and emergency patients annually.

The donation made by Dr. Danter and Mr. Kelly will be applied to a fund used specifically for oncology research and treatment initiatives. The donation is aligned with COTI's corporate value of improving lives by enabling accelerated development of new effective treatment options, and is in an area of specific scientific interest to COTI which has three libraries in oncology under development; small cell lung cancer, acute myelogenous leukemia, and colorectal cancer.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and pre-clinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds (small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, colorectal cancer, and acute myelogenous leukemia in adults) are under active development.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information